Because constitutive activation of the MAPK pathway in thyroid cancer frequently represses NIS expression and function and is associated with decreased radioiodide uptake and poor patient prognosis, many studies have focused on MAPK inhibitors (Dunn et al., 2019; Ho et al., 2013). The gene discussed is SLC5A5; the disease is thyroid cancer.